The first platform to facilitate the licenced importation of medical cannabis into Europe has formally launched in the UK. Astral Health will act as a gateway to the European cannabis market, providing a simple and efficient system for the licenced import and distribution of approved medical cannabis products. German, Italian, French and Spanish market announcements will follow over the coming weeks.
The company will provide European patients living with a range of chronic and debilitating conditions with life-changing access to the best medical cannabis products available by offering a streamlined end-to-end system for bringing products into the market. Its services include support on market access, approvals and navigating the regulatory system, as well as education, training and intelligence.
The launch of the end-to-end platform follows the formation of a new UK joint venture between ECH and Miller & Miller Chemicals Ltd. The agreement formalises their existing working relationship as experts in this field and is demonstrative of their shared commitment to providing better access for patients.
This close partnership between the two companies means that Astral, which will provide a full suite of services to those in the medical cannabis sector, benefits from significant expertise around logistics and distribution, while building on Miller & Miller and ECH's market-leading knowledge of the medical cannabis market and the regulatory approvals process in key markets.
Dean Friday, ECH CFO & Director, said: "The launch of Astral Health is a pioneering step forward that will support increased market access to medical cannabis across Europe. The legalisation of prescription cannabis in the UK has given people with chronic illnesses hope; the next step is to ensure the availability of this medication to those who need it. By facilitating the licensed import of approved medical cannabis products on an ongoing contractual basis through Astral Health, that's what we are working to achieve."